Abstract
On July 29, 1998, the Food and Drug Administration (FDA) licensed North American Vaccine, Inc. (Beltsville, Maryland) to distribute a combined diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (Certiva) for the first four doses of the diphtheria and tetanus toxoids and pertussis vaccination series administered to infants and children aged 6 weeks-6 years. Certiva is the fourth acellular pertussis vaccine to be licensed for use in infants and young children in the United States.
Highlights
This study focused on children enrolled at Group Health Cooperative of Puget Sound (GHC), a Seattle-based
After adjusting for sex, trends over time, Medicaid status, and primary clinic, GHC children receiving inactivated poliovirus vaccine (IPV) as their first polio vaccination were as likely to be upto-date at age 12 months as children receiving oral poliovirus vaccine (OPV)
Measurements from NHANES III conducted during 1988-1994; the findings indicate that most estrogen-deficient women in the United States who had femoral osteoporosis based on bone mineral density (BMD) were unaware of having this condition, reflecting the evolving nature of research and clinical practice regarding osteoporosis
Summary
Recommended adoption of a sequential inactivated poliovirus vaccine (IPV)oral poliovirus vaccine (OPV) vaccination schedule.[1]. After adjusting for sex, trends over time, Medicaid status, and primary clinic, GHC children receiving IPV as their first polio vaccination were as likely to be upto-date at age 12 months as children receiving OPV CDC Editorial Note: The findings in this report indicate that use of IPV for the initial polio vaccine doses in these two West coast HMOs was not associated with decreases in vaccination coverage levels These findings are consistent with evaluations conducted in other settings, including clinics serving children from lowincome families.[4,5,6]. FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION vaccination schedule was implemented to a much greater degree in the HMO that used a more centralized decision making process than in the HMO that relied on local decision making (82% compared with 36%, respectively, for the percentage of children who received IPV for their initial polio vaccination). OPV remains the vaccine of choice for mass vaccination campaigns to control outbreaks associated with wild poliovirus
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
